Topical Therapy Update: Atopic Dermatitis

This transcript discusses advancements in topical therapies for atopic dermatitis. The speaker emphasizes the importance of anti-inflammatory treatments while also highlighting the need for patient education about skincare. They outline various treatment options available for moderate atopic dermatitis, noting the evolution of therapies, including the introduction of non-steroidal medications like topical calcineurin inhibitors, riflumilast, and ruxolitinib. Significant attention is given to the concern surrounding steroid phobia, fueled by social media, which impacts treatment compliance and can lead to severe outcomes in patients reluctant to use topical corticosteroids. The speaker analyzes recent studies, including a Cochrane review and various clinical trials, emphasizing the difficulties in comparing older treatments with new ones and the varying efficacy rates of traditional corticosteroids versus newer agents. There is also discussion about the complexities of chronic hand eczema and the ongoing development of targeted therapies, which could improve care in this area. Overall, the landscape of topical therapy for atopic dermatitis is changing, with the introduction of novel agents that offer promising alternatives to corticosteroids, prompting a reconsideration of treatment regimens to better meet patient needs.